Zoetis breaks ground on global manufacturing, supply, R&D complex in China

Suzhou, China
The new innovation and manufacturing facility will include 43,000 square meters of vaccine manufacturing operations and laboratory space. (Christian Gänshirt/CC BY-SA 4.0)

Pfizer animal health spinoff Zoetis officially broke ground for its combo complex in Suzhou, China, that will house a global manufacturing, supply and research and development center.

The new innovation and manufacturing facility will include 43,000 square meters of vaccine manufacturing operations and laboratory space. Construction is expected to be completed and the plant certified by Chinese authorities by 2021.

The cost of the project hasn’t been disclosed. Zoetis reported revenue of $174 million in China in 2017. The company began operations in China in 1995 and has approximately 600 employees and commercial headquarters in Shanghai. 

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“With this new center for vaccine innovation co-located with expanded manufacturing capabilities in Suzhou, and a team of highly trained field representatives, we are well-positioned to help China’s livestock farmers answer increasing demand for a safe and abundant supply of pork, milk, beef and fish,” Mike Wang, SVP for Zoetis in China, said in a statement.

When completed, the facility in Suzhou will focus on development and production of vaccines for swine, cattle, fish and companion animals in China. According to Vetnosis, China is the world’s second largest animal health market, valued at $4.3 billion in 2017. 

In 2015, Zoetis acquired aquatic vaccine maker Pharmaq for $765 million. A year later it paid $85 million for Nexvet, which develops species-specific monoclonal antibodies to treat osteoarthritis pain and other disorders in companion animals.

Read more on

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.